Illumina and Agilent Technologies to Co-Market Targeted Resequencing Solution
News Apr 21, 2009
Illumina, Inc. and Agilent Technologies announced they have entered into a non-exclusive co-marketing agreement to support a new, scalable solution for researchers conducting targeted resequencing studies. The Agilent SureSelect Target Enrichment System, optimized for Illumina’s widely-adopted next-generation sequencing platform, the Genome Analyzer, provides researchers with a method for resequencing specific regions of interest in the genome.
This approach simplifies the lab process while providing even coverage and high alignment rates. When combined with Illumina’s Genome Analyzer, the Agilent SureSelect Target Enrichment System allows researchers to conduct studies that otherwise would not be feasible.
Illumina and Agilent are highlighting the benefits of their combined solution at the American Association of Cancer Research (AACR) meeting this week in Denver, Colorado. The new research protocol enables scientists to interrogate multiple regions of interest in order to detect rare mutations.
Chad Nusbaum, Co-director of the Genome Sequencing and Analysis program at MIT’s Broad Institute, described the hybrid selection technique utilized by Agilent’s SureSelect technology in the February 2009 issue of Nature Biotechnology.
“We have developed a hybrid-selection method for enriching specific subsets of a genome that is flexible, scalable, and efficient. Targeting based on hybrid selection may be potentially useful for a variety of applications where traditional single-plex PCR is either too costly or too specific. Examples are enrichment of precious ancient DNA that is heavily contaminated with unwanted DNA, deep sequencing of viral populations in clinical samples, or metagenomics analyzes of environmental or medical specimens.”
“A partnership with Agilent underscores our commitment to build upon the utility of our next-generation sequencing technology, helping researchers plan and execute studies at a scale never before possible,” said Jay Flatley, President and CEO of Illumina. “We continue to expand our portfolio of solutions with powerful tools for studying genetic variation. This solution provides the research community with a cost-effective, automation-friendly, and flexible approach to targeted resequencing for a wide variety of applications.”
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews
A new technique that prolongs the lifespan of blood samples could be a breakthrough for liquid biopsy assays.READ MORE